- •The risk of hepatocellular carcinoma is not increased after therapy with DAAs.
- •The incidence of hepatocarcinoma declines one year after the start of therapy.
- •In our cohort, tumor incidence was higher in patients without HCV eradication.
- •Risk factors of hepatocarcinoma after DAA therapy are the same as for HCV-related cirrhosis.
Background & Aims
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Hepatology
Author names in bold designate shared co-first authorship
- Hepatitis C virus infection.Nat Rev Dis Primers. 2017; 3 ([Review]): 17006
- New hepatitis C therapies: the toolbox, strategies, and challenges.Gastroenterology. 2014; 146: 1176-1192
- For the ASTRAL-1 Investigators Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.N Engl J Med. 2015; 373: 2599-2607
- Safety and efficacy of Elbasvir/Grazoprevir in patients with Hepatitis C, Virus infection and compensated cirrhosis: an Integrated Analysis.Gastroenterology. 2017; 152: 1372-1382
- Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.Gut. 2016; 65: 1861-1870
- Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.J Hepatol. 2016; 64: 1224-1231
- Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis.N Engl J Med. 2015; 373: 2618-2628
- Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease.Gastroenterology. 2015; 149: 649-659
- Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study.J Hepatol. 2016; 65: 524-531
- Reversion of disease manifestations after HCV eradication.J Hepatol. 2016; 65: 95-108
- Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.J Hepatol. 2016; 65: 741-747
- Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease.Hepatology. 2017; ([Epub ahead of print])
Delmonte RJ, Andrews B, Richards LM, Soto R, Collier S, Kuo A et al. Treatment of HCV with direct acting antivirals significantly reduces liver related hospitalizations in patients with cirrhosis. AASLD. The Liver Meeting 2017 Washington DC. October 20–24.
- Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.J Hepatol. 2016; 65: 719-726
- Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with SVR following IFN-free DAA treatment.J Hepatol. 2016; 65: 856-858
- Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.J Hepatol. 2016; 65: 727-733
- Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution.J Hepatol. 2016; 65: 663-665
- Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection.J Med Virol. 2016; 89: 476-483
- Follow-up of sustained virologic responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment.Liver Int. 2017; ([Epub ahead of print])
- Sustained virological response to interferon is associated with improved outcome in HCV-related cirrhosis: A Retrospective Study.Hepatology. 2007; 48: 579-587
- Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in hepatitis C patients with advanced fibrosis.J Hepatol. 2010; 52: 652-657
- Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications.Gut. 2004; 53: 744-749
- The natural history of compensated cirrhosis due to hepatitis C virus: a 17-Year Cohort Study of 214 Patients.Hepatology. 2006; 43: 1303-1310
- Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.J Hepatol. 2016; 66: 485
- Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.J Hepatol. 2017; 67: 1204-1212
- Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents.Gastroenterology. 2017; 153: 996-1005
- HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma.J Hepatol. 2018; 68: 25-32
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma.J Hepatol. 2012; 56: 908-943
- Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C.Hepatology. 1994; 20: 15-20
http://www.webaisf.org/media/39700/documento_hcv_241017.pdf. Aghemo A, Bruno R, Ciancio A, Coco B, Petta S. AISF 2014.
Decreto_222_4.8.15_LineeIndirizzoDAA_EpC.pdf. Alberti A, Vincenzi V, De Boni M, Carlotto A, Pellizzer G, Fabris P, et al. Veneto Region 2015.
- Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.J Hepatol. 2017; 68: 526-549
- Hepatocellular carcinoma decreases the chance of successful Hepatitis C virus therapy with direct-acting antivirals.J Hepatol. 2017; 66: 1173-1181
- Molecular mechanisms of hepatitis C virus-induced hepatocellular carcinoma.Clin Microbiol Infect. 2016; 22: 853-861
- Natural killer cells phenotypic characterization as an outcome predictor of HCV-linked HCC after curative treatments.Oncoimmunology. 2016; 5e1154249
- Immunological analysis during interferon-Free therapy for Chronic Hepatitis C Virus infection reveals modulation of the natural killer cell compartment.J Infect Dis. 2016; 213: 216-223
- Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function.Gastroenterology. 2015; 149: 190-200
- Direct-acting antiviral induced hepatitis C virus clearance does not completely restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C.J Infect Dis. 2016; 214: 1965-1974
- Dynamic changes of post-translationally modified forms of CXCL10 and Soluble DPP4 in HCV subjects receiving Interferon-Free Therapy.PLoS One. 2017; 10: 1-9
- Patterns of hepatocellular carcinoma development in hepatitis B virus and hepatitis C virus related cirrhosis.Antiviral Res. 2001; 52: 199-207